Exen-plary glucose control

The last ten years have seen rapid developments in the management of diabetes, and the introduction of exenatide, a GLP-1 receptor agonist, is slowly taking to the marketplace, joining agents such as sitagliptin and pioglitazone. How effective is it?

The DURATION-2 study looked at once weekly exenatide compared with sitagliptin and pioglitazone. Exenatide consistently lowered the HbA1c more than the other two, weith greater weight loss and well. 

It must be noted that the study was funded by Eli Lilly and Amylin, and that going to exenatide brings with it significant cost. That said, the results are impressive, and if you sneak a peek at DURATION-3 (comparing exenatide with insulin), exenatide again edged slightly ahead. 

Read about it here

IMAGE: Amylin/Lilly


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s